Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymic tissue that plays a key role in immune system regulation. It is the most well-characterized thymic peptide and is produced commercially by solid-phase synthesis. Thymosin Alpha-1 enhances both innate and adaptive immune responses by modulating dendritic cell function, promoting T-cell maturation, and stimulating cytokine production. The peptide is approved in over 35 countries for treatment of chronic hepatitis B, hepatitis C, and as an immune adjuvant in cancer therapy. It has also shown potential in treating other infectious diseases and immunodeficiency conditions.
| Research Status | Approved (Asia, Latin America) |
|---|---|
| Half-Life | 2 hours |
| Administration | Subcutaneous injection |
| Typical Dosage | 1.6 mg twice weekly |
| Molecular Weight | 3,108 Da |
| Molecular Formula | C129H215N33O55 |
Enhances T-cell function, dendritic cell maturation, and overall immune surveillance.
All information is presented for Research Use Only (RUO). Not medical advice.